Management of peritoneal metastases from colorectal cancer and small bowel adenocarcinoma in patients with inflammatory bowel disease

Table 3 Oncological outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with and without inflammatory bowel disease with peritoneal metastases

Feature1	Ben-Yaacov et al[45], 2024		Hammoudi et al[21], 2018
	IBD cohort (n = 10)	Non-IBD cohort (n = 222)
Median overall survival1	19.6 months (P = 0.056)2	53.2 months	24 months (vs 44.3 months in sporadic; HR4 = 4.47)
Median disease-free survival1	4.9 months (P = 0.174)	9.4 months	RFS 8.3 months vs 12.9 months (HR = 2.31)
Recurrence pattern3			10/11 relapsed; median 7.2 months; 8/10 peritoneal

¹Median overall survival/disease-free survival/recurrence-free survival: Time from cytoreductive surgery with hyperthermic intraperitoneal chemotherapy to death (overall survival) or recurrence (disease-free survival/recurrence-free survival); censored at last follow-up.

²P values indicate statistical comparison. P < 0.05 considered significant but interpret cautiously in small samples due to wide confidence intervals and limited power.

³Recurrence pattern: Specify proportion of recurrences that are peritoneal. Early recurrence within first year post-cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

⁴Hazard ratios compare risk of event (death or recurrence) between inflammatory bowel disease and non-inflammatory bowel disease cohorts. Include 95% confidence intervals when available.

IBD: Inflammatory bowel disease; RFS: Recurrence-free survival; HR: Hazard ratio.